

## PAN MERSEY AREA PRESCRIBING COMMITTEE MEETING

Minutes of the Meeting held on Wednesday 30 March 2016 in  
Kent Lodge, Broadgreen Hospital, Thomas Drive. L14 3LB

**Present:**

MEMBERS		Present	Apologies
Dr Sid McNulty (Chair)	Consultant Endocrinologist/Chair Drug & Therapeutics Committee – St Helens & Knowsley Teaching Hospitals NHS Trust	X	
Peter Johnstone (Deputy Chair)	Prescribing Commissioner – Liverpool CCG	X	
Isam Badhawi	Senior Pharmacist – Liverpool Women’s NHS Foundation Trust	X	
Catrin Barker	Chief Pharmacist – Alder Hey Children’s NHS Foundation Trust	X	
Dr Rob Barnett	LMC Representative, Liverpool		X
Nicola Baxter	Head of Medicines Optimisation – West Lancs CCG		X
Becky Birchall	Senior Pharmacist, NHS Halton CCG		X
Alison Butt (Maureen Hendry attending)	Joint Head of Medicines Management - Liverpool Community Health		X
Nicola Cartwright	Acting Deputy Head of Medicines Management, St Helens CCG	X	
Neil Chilton	Deputy Chief Pharmacist, 5 Boroughs Partnership, Mental Health Trust	X	
Dr Catherine Doyle	Clinical Lead Meds Management– Warrington CCG		X
Alison Ewing	Clinical Director Pharmacy – The Royal Liverpool & Broadgreen University Hospitals NHS Trust		X
Dr Anna Ferguson	GP Clinical Lead – South Sefton CCG	X	
Dr Claire Forde	CCG Governing Body Member, Prescribing Lead – Halton CCG	X	
Simon Gelder (Mike Welsby attending)	Chief Pharmacist – St Helens & Knowsley Teaching Hospitals NHS Trust		X
Margaret Geoghegan (Nicola Cartwright attending)	Head of Medicines Management – St Helens CCG		X
Donna Gillespie-Greene	Deputy Head of Medicines Management – Midlands & Lancashire Commissioning Support Unit	X	
Gillian Gow	Chief Pharmacist – Liverpool Heart & Chest Hospital NHS FT	X	
Dr Dan Hawcutt	Consultant Paediatrician and Chair of D&T Alder Hey Children’s NHS FT	X	
Maureen Hendry	Practice pharmacist/Interface support pharmacist, L’pool Community Health (representing Alison Butt)	X	
Dr Aftab Hossain	Clinical Lead, Prescribing – Knowsley CCG		X
Jenny Jones (representing Diane Matthew)	Principal Pharmacist Meds Management – Warrington & Halton Hospitals NHS FT	X	
Dr Tom Kennedy	Consultant at RLBUHT and Chair of D&T	X	
Lee Knowles	Chief Pharmacist – Mersey Care NHS Trust		X
Jenny Lunn	Pharmaceutical Adviser & Team Lead, Medicines Management – Warrington CCG	X	
Susanne Lynch	CCG Lead Medicines Management – South Sefton CCG and Southport & Formby CCG	X	

Diane Matthew (Jenny Jones attending)	Chief Pharmacist, Warrington & Halton Hospitals NHS Foundation Trust		X
Dr Neil Mercer	Consultant Anaesthetist/Chair Drug & Therapeutics Committee –Aintree University Hospitals NHS Trust	X	
Paul Mooney	Medicines Management Lead, RLBUHT (representing Alison Ewing & Paul Skipper)	X	
Kath Phillips	Pharmacist – Southport and Ormskirk NHS Trust	X	
Mark Pilling	Interim Head of Medicines Management – Knowsley CCG	X	
Dr Andrew Pryce	Chair, Knowsley CCG		X
Lucy Reid	Lead Pharmacist – Halton CCG Locality Medicines Management Team	X	
Dr Shamim Rose	GP Prescribing Lead & Board Sponsor – Liverpool CCG		X
David Sanchez	Liverpool LPC Representative	X	
Paul Skipper	Deputy Director of Pharmacy – The Royal Liverpool & Broadgreen University Hospitals NHS Trust		X
Dave Thornton	Principal Pharmacist, Clinical Services, University Hospital Aintree	X	
Mike Welsby	St Helens & Knowsley Teaching Hospitals NHS Trust (representing Simon Gelder)	X	
Dr Julie Whittaker	St Helens CCG Governing Body Medicines Management Lead GP		X
Dr David Wilson	LMC Representative, Mid-Mersey LMC		X
<b>IN ATTENDANCE</b>			
Vicki Caton	Clinical Services Manager, Southport & Ormskirk NHS Trust	X	
Anne Henshaw	Senior Pharmacist – Midlands & Lancs CSU	X	
Sarah McParland	Lead Pharmacist - KIPPS		X
Agatha Munyika	Mersey Care NHS Trust		X
Graham Reader	Senior Pharmacist – Midlands & Lancs CSU	X	
Helen Stubbs	Senior Pharmacist – Midlands & Lancs CSU	X	

1	<p><b>APC/16/18 – Welcome and Apologies for Absence</b></p> <p>The Chair welcomed members and accepted the apologies of the following:</p> <p>Agatha Munyika, Alison Butt (Maureen Hendry attending), Ashley Baldwin, Andrew Pryce, Becky Birchall, Sarah McParland, Simon Gelder (Mike Welsby attending), Dr Lisa Manning, Dr Catherine Doyle and Dr Julie Whittaker.</p>	<b>Action:</b>
2	<p><b>APC/16/19 – Declarations of Interest and Quoracy Check</b></p> <p>A quoracy check confirmed that this meeting was not quorate. There was one declaration of interest – see item 16/21/02.</p>	
3	<p><b>APC/16/20 – Minutes of the previous meeting and matters arising.</b></p> <p><b>16/20/01 – Minutes from the Previous Meeting</b></p> <p>The Minutes were agreed to be an accurate record of the previous meeting on 24 February 2016.</p> <p><b>16/20/02 – Matters Arising</b></p> <p><b>APC Chair Nominations</b></p> <p>There have been no new declarations of interest since the last APC Meeting. As a preference had been expressed, for the next chair to be a GP, the Chair asked the two GPs present if they wished to put their names forward but they declined. Peter Johnstone has put his name forward only on the basis that no GPs or other members have volunteered and if this is still the case by the time of the next APC Meeting then a vote will be taken at the April meeting for this appointment.</p>	<b>ALL</b>

	<p><b>APC Venues</b></p> <p><u>Kent Lodge</u>: The room is free of charge but only available from 2-4pm. Parking in the multi-storey carpark opposite Kent Lodge is £2.70 up to 2 hours and £3.40 for 2-4 hours.</p> <p><u>River Alt Resource Centre</u>: The room cost is £40. It is available 1.30-3.30pm. Although there is free parking, not all members managed to park in the car park last month and a few had to park in the surrounding roads.</p> <p><u>Decision</u>: Members were asked for their preference of venue/time. A vote was taken and 9 members voted for Kent Lodge and 7 members voted for River Alt Resource Centre.</p> <p><b>Amendment to Antimicrobial Guideline</b></p> <p>In the February APC Meeting members expressed concern about the advice on administration of IM benzylpenicillin in Community Acquired Pneumonia if admission is delayed, following a change in the BTS guideline on pneumonia.</p> <p>Alternative wording has now been produced for the Antimicrobial Guideline to ensure that there is no unnecessary delay in the administration of antibiotics if there is likely to be a delay in hospital admission:</p> <p><i>‘Administer benzylpenicillin 1.2g IM/IV or amoxicillin 1g orally immediately where the illness is considered to be life threatening or if there is likely to be a delay in admission’</i></p> <p>The APC Committee approved the above proposed wording.</p>	
4	<p><b>APC/16/21 – New Medicines</b></p> <p><b>16/21/01 – Grey Statement Summary</b></p> <p><u>Abiglutide</u>: This was identified at horizon scanning and a grey statement has been produced. It will be reviewed during 2016/17.</p> <p><u>Ezetimibe</u>: A grey statement has been produced but this will only apply where patients have cholesterol levels within target range as other patients would be covered by NICE TA385. This drug will be reviewed if a formal application is received and prioritised for in-year review.</p> <p>All agreed to the above.</p> <p><b>16/21/02 – Ezetimibe for hypercholesterolaemia</b> (PJ declared an interest in Merck Sharp and Dohme Ltd.)</p> <p>This statement has been updated in line with NICE TA385 (Feb 2016) in order to make it clear what the NICE recommendations are. This is unchanged from the previous NICE TA and statins remain the first choice treatment for hypercholesterolaemia.</p> <p>The APC agreed to this statement.</p> <p><b>16/21/03 – Ulipristal for uterine fibroids</b></p> <p>The NMSG have updated this statement with assistance from Liverpool Women’s Hospital. The NICE clinical guidance dates back to 2007, with updated NICE guidance expected in August 2016. It was previously Red as only licensed for a single treatment course and the provider Trust was expected to supply the full course. It has recently received a license extension to allow repeated intermittent use and has now been recategorised as Amber Retained, although the initial course should still be supplied in full by the provider Trust. Following specialist review, further courses may be requested to be prescribed by the patient’s GP if appropriate. It was suggested that the statement was not entirely clear whether this was just for pre-operative treatment or not, so it was agreed that the NMSG will add further narrative in the formulary to make it clear.</p> <p>This statement was agreed with the extra wording added to NetFormulary.</p> <p><b>16/21/04 – Qlaira for heavy menstrual bleeding</b></p> <p>This is a routine 2-yearly update. There are no major changes. The SPC information and the BNF reference have been updated, along with the costing information.</p> <p>Members agreed to this statement and the Green status.</p> <p><b>16/21/05 – Qlaira for oral contraception</b></p> <p>This is a routine 2-yearly update with no major changes.</p> <p>The APC agreed to this statement and to the Black RAG rating.</p>	

5	<p><b>APC/16/22 – Formulary and Guidelines</b></p> <p><b>16/22/01 – Triptorelin statement</b></p> <p>The statement has reached its expiry date and has been slightly updated with regard to references. The only significant change is to RAG rating, changing from Amber to Amber Patient Retained. Some feedback suggested it should stay as Shared Care, but Amber Patient Retained was previously agreed by APC when it reviewed the original list of shared care drugs. Other feedback was received regarding some changes in wording and this has been addressed. It was pointed out to members that there is a new brand of leuprorelin (Lutrate) and FGSG will look at this separately. The statement was agreed.</p> <p><b>16/22/02 – Blood Glucose Testing Strips guideline</b></p> <p>This statement was due for review last year but had been delayed until NICE guidelines (NGs 17, 18 and 28) on diabetes had been published, and these recommendations have been incorporated. In response to feedback comments, on page 2, information about Cystic Fibrosis patients has been added and also notes about ketone testing. The guideline was agreed.</p> <p><b>16/22/03 – Anthelios XL Cream</b></p> <p>The FGSG proposed the addition of Anthelios XL cream to formulary section 13.8.1 as Green and proposed the removal of Uvistat cream. Feedback from the consultation email was either no comment or was in agreement. This change was agreed by the APC.</p> <p><b>16/22/04 – Dronedarone statement</b></p> <p>At Oct 2015 meeting the APC were presented with this draft statement and consultation feedback, and felt this should be Amber Patient Retained but asked FGSG to write a framework document to support prescribers. This has now been drawn up by the subgroup, detailing required monitoring and designating the responsible doctor and timings. Consultation feedback on the framework was that it was helpful. However feedback from some CCG commenters was they believed it should be a Red drug or Shared Care drug.</p> <p>There was subsequent debate about the RAG status of dronedarone and members' safety concerns. There were some views that while on paper the framework was satisfactory, in practice ensuring correct monitoring could be difficult particularly around communication. Several members felt that Shared Care would be the only viable way forward at this time. A vote was taken as to whether this drug should be Red, Amber Patient-Retained or Shared Care (1 vote for Red, 4 votes for Amber-retained and 11 votes for Shared Care).</p> <p>The APC agreed to change the status to Shared Care, draft a proposed Shared Care Protocol and this will be sent out for consultation.</p> <p><b>16/22/05 – Botulinum toxin in anal fissure statement</b></p> <p>This statement has undergone its routine 2 yearly review. The only changes made are to the prices, dates of references and a couple of spelling changes. The statement was agreed.</p> <p><b>16/22/06 – Formulary amendments</b></p> <ul style="list-style-type: none"> <li>• Addition of methylphenidate (Medikinet XL brand) 50mg and 60mg to formulary section 4.4 as Amber.</li> <li>• Addition of ivacaftor 50mg and 75mg granule sachets to formulary section 3.7 as Red.</li> <li>• Note existence of Butec brand of buprenorphine patch for information in formulary section 4.7.2</li> <li>• Addition of Fostair (beclomethasone and formoterol) 200/6 metered dose inhaler and NEXThaler dry powder inhaler to formulary section 3.2 as Green.</li> </ul> <p>The APC Committee agreed to the above amendments to the Pan Mersey formulary.</p>	
6	<p><b>APC/16/23 – Safety</b></p> <p><b>16/23/01 – Prolonged use of Proton Pump Inhibitors (PPIs) Statement</b></p> <p>The APC agreed to this safety statement.</p>	

	<p><b>16/23/02 – Administration of Insulin</b></p> <p>Previously the Safety Subgroup had tried but not received feedback from the Cheshire and Merseyside Diabetic Network, on the two proposed documents. However, Dr Ahmad brought this to the Network and feedback has now been received. There were a couple of minor changes suggested and these have been made.</p> <p>A question was raised about whether these documents related to children, these were to replace the Blue Book used by district nurses and it is believed that children do not get given insulin by district nurses so likely not to be relevant.</p> <p>It was confirmed that use of these documents in place of the Blue Book is not mandatory, they were produced to be helpful. This work was produced in response to a number of insulin errors. On the Pan Mersey website, wording will be used along the lines of “this is a sample document – check with your local provider/practice.” To begin with, it will be put on the website as a PDF document.</p> <p>The APC committee agreed to these documents on the basis that it is a recommendation rather than mandatory.</p>	
7	<p><b>APC/16/24 – Any Other Business</b></p> <p><b>16/24/01 – AOB</b></p> <p><u>MHRA information for Valproate</u></p> <p>It was brought to the attention of the meeting that, following the MHRA Leaflet for adults, there will be a leaflet produced which is aimed at informing children and parents of the risks.</p> <p><u>April APC Meeting and Doctors’ Strike</u></p> <p>Hospital colleagues confirmed that if the proposed junior doctors’ strike goes ahead on 27 April then they will be unable to attend the next APC meeting. Therefore it was agreed to move the meeting to 4 May if the strike is confirmed.</p>	
8	<p><b>APC/16/25 Date, Time and Venue of the next meeting</b></p> <p>Date and time of next APC meeting: TO BE CONFIRMED.</p>	

***The agenda and minutes of this meeting may be made available to public and persons outside of The Pan Mersey Area Prescribing Committee Health Community in order to comply with requests made under the Freedom of Information Act 2000.***